About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Broad scientists oust Alzheimer’s risk gene in a lab dish by revising DNA

Photo Courtesy of Stephen Dixon/the McGovern Institute

The CRISPR family enzyme CAS13 (pink) uses a special guide (red) to target RNAs in the cell (blue). Broad Institute scientists used a new model of CRISPR, CAS13, to try to eliminate a genetic risk for Alzheimer’s disease, they report in the journal Science.

With a newly adapted CRISPR tool, researchers out of the Broad Institute of MIT and Harvard, have stamped out an Alzheimer’s threat in cells by revising RNA, rather than permanently editing DNA.

The findings were reported in the July 11, 2019 issue of the journal Science.

Feng Zhang, PhD and colleagues illustrated the promise of the new CRISPR platform, CAS13, by deactivating the APOE4 risk gene and changing it to APOE2, the rarer variant (which is protective and may actually decrease a person’s risk for Alzheimer’s: Science). Long viewed as one of the biggest risk factors for Alzheimer’s – APOE4 is also associated with the most common form of the disease.

Because protein-coding RNA is transcribed from genomic DNA, this technique offers the potential to correct disease-causing mutations at the RNA level without the possible risks of making permanent changes to the genome. In addition, in some cell types, particularly postmitotic cells such as neurons, it is difficult to edit genomic DNA using earlier CRISPR approaches. Therefore, CAS13 represents a potential new strategy to treat devastating diseases that affect the brain, including Alzheimer’s.

The new advance, called RESCUE for RNA Editing for Specific C to U Exchange, builds on REPAIR, a technology developed earlier by Zhang and his team that changes adenine bases into inosine in RNA. The scientists took the REPAIR fusion and evolved it in the lab until it could change cytosine to uridine.“Development of RESCUE demonstrates the power of protein engineering of natural processes,” said Deerfielder Bob Jackson, MD. “The ability of RESCUE to edit from C to U increases the number of pathogenic mutations targetable by RNA editing. It also adds capacity to potentially edit important signaling residues.”

CRISPR refers to Clustered Regularly Interspaced Short Palindromic Repeats that occur in the genome of certain bacteria, from which the system was discovered. Often thought of as “molecular scissors”, the CRISPR technology enables researchers to remove, add or alter specific DNA and RNA sequences in the genome of higher organisms, with the goal of curing disease.

The Broad has been a Deerfield collaborator since 2017: Broad Institute and Deerfield Management launch innovative partnership to tackle serious unmet medical needs

Adapted from MIT news release